Using Ficoll-Hypaque-separated cells, monocyte chemotaxis was measured by an agarose technique in patients with increased susceptibility to infection, with atopic dermatitis, and in individuals taking aspirin. I n vitro effects of aspirin, hydrocortisone, aminophylline, ephedrine, and diphenhydramine were also studied. Significantly decreased chemotaxis was found in one 9-year-boy with severe mucocutaneous candidiasis and three of 22 patients with atopic dermatitis. In the atopic group of patients greater than 10 years of age, mean monocyte chemotaxis was significantly decreased from the age-matched control group. This decrease did not correlate with serum IgE levels, absolute blood eosinophil counts, or clinical symptom scores. Following aspirin ingestion, mean monocyte chemotaxis significantly decreased whereas neutrophil chemotaxis was unaffected. Using therapeutic concentrations, drug levels of aspirin and aminophylline in vitro caused greater than 35% inhibition of monocyte movement.
atopic dermatitis. In the atopic group of patients greater than 10 years of age, mean monocyte chemotaxis was significantly decreased from the age-matched control group. This decrease did not correlate with serum IgE levels, absolute blood eosinophil counts, or clinical symptom scores. Following aspirin ingestion, mean monocyte chemotaxis significantly decreased whereas neutrophil chemotaxis was unaffected. Using therapeutic concentrations, drug levels of aspirin and aminophylline in vitro caused greater than 35% inhibition of monocyte movement.
Speculation
Measurement of monocyte chemotaxis in immunodeficiency and atopic disease may uncover defects amenable to agents which stimulate cell movement.
(1). Nezelof syndrome (I), and DiGeorge syndrome (I). Five patients with recurrent respiratory infections of unknown cause, six children with cystic fibrosis, and eight adults with chronic renal failure prior to dialysis were also investigated.
We also studied 22 patients with atopic dermatitis ranging in age from 17 months to 24 years (mean age, 10.2 years). There were 16 males and 6 females with a mean duration of the dermatitis of 8.3 years. Sixteen of these patients had asthma, and 15 had allergic rhinitis. Concurrent treatments within one week of the study included corticosteroid creams (14 of 22) , hydroxyzine (I l of 22) . diphenhydramine (4 of 22) , prednisone (1 of 22) . Marax (ephedrine sulfate, theophylline, hydroxyzine, and ethyl alcohol) (2 of 22) . and theophylline (1 of 22) (PO medications were withheld for at least 6 to 12 hr prior to testing). In addition to chemotaxis determination, total serum IgE by Phadebas RIST method, total absolute blood eosinophil counts by Pilot technique (22) , and a clinical symptom score were determined. The latter, adapted from the scoring system of Rachelefsky et al. (23) was based upon eight criteria: (I) erythema; (2) vesiculation; (3) crusting; (4) excoriation; (5) lichenification; (6) pigmentation; (7) pruritus; and (8) sleep loss. Gradations were given to each criteria (0 to 4) depending on the number of body areas involved. A total score was determined which ranged from 0 (maximally severe disease) to 32 (no disease).
A third study group consisted of eight adult volunteers who ingested 3.9 g-of aspirin daily for th;ee days. Monocyte and ~~f~~~i~~ monocyte chemotaxis has been observed in a variety neutrophil chemotaxis were measured pre-and postaspirin ingesofdiseases, including chronic mucocutaneous candidiasis (1 1, 271, tion. Serum salicylate concentrations were measured by the UCLA Wiskott-Aldrich syndrome (i), Chediak-Higashi syndrome (12) . clinical laboratory. atopic dermatitis (10, 25, 29) , malignancy (28) , and viral infections
In vitro effects on monocYte chemotaxis were determined by ( 16) . Developmental monocyte chemotaxis defects have also been adding varying ancentrations of h~drocortisone sodium succinate noted in normal newborns and young children utilizing endotoxin (Soh-Cortef; The Upjohn CO., Kalamazoo, MI), ephedrine sulfate or zymosan-activated serum as the chemotactic factor (15, 31) .
(Abbott Laboratories, North Chicago, IL), aminophylline ethylThe majority of these studies used the Boyden chamber tech-enediamine (Amersham/Searle Corp., ~r l i n~t o n ~eights, IL), nique. A sensitive method of measuring chemotaxis under agarose, diphenhydramine ( P a r k Davis and C0.v Detroit, MI) and amdescribed by Cutler (6) (5) , severe combined immunodeficiency (RPMI) with 5% fetal calf serum to a final concentration of 10' (I), congenital agammaglobulinemia (5), Job-Buckley syndrome MN's/ml. Polymorphonuclear leukocytes were separated by sed-imentation using 15% sterile Plasmagel according to the method of Forman and Stiehm (32) . Serum samples were stored at -20°C until tested.
Monocyte chemotaxis was measured using a Cutler technique adapted by Klein el al. (15) . In this assay, 1.5 ml of a 0.75% electrophoresis grade agarose in medium 199 with 10% fetal calf serum is plated in a 35-x 10-mm diameter disposable plastic Petri dish. Three wells, 4 mm in diameter and 2 m m apart, are made in the agarose plate with a template punch, and then the plugs are removed with suction. Ten pI of MN cells (107/ml) are added to the central well, 10 p1 of chemotactic factor are added to the left well, and 10 p1 of normal saline are added to the right well (Fig.  I ). All assays are done in triplicate. The agarose plates are incubated at 37OC in a 5% C 0 2 atmosphere for 18 hr. Counting is facilitated by using a microscope 5-x 5-mm eyepiece grid; this is aligned between the center well and a peripheral well to form a vertical column. Cells in both columns are counted using an x 10 magnification and expressed as the mean migrating cells per plate (cells migrating toward activated serum minus cells migrated towards saline). The agarose plates can be fmed by adding 1.5 ml of absolute alcohol to the plate for 4 hr. The agarose is then removed, and the plate is stained with Wright's stain.
Polymorphonuclear (PMN) chemotaxis was similarly measured but using cell suspensions of 2.5 x lO%eIls/ml and an incubation period of 3 hr. Age-matched chemotaxis values for both monocytes and neutrophils were previously reported in our laboratory (15); day control determinations from normal adults were measured for each experiment.
The chemotactic factor for all assays was zymosan-treated serum. Three ml of human serum of a standard adult donor was added to 0.15 g of zymosan at 37°C for 30 min, centrifuged at 900 x g for 10 min, inactivated at 56°C for 30 min, and stored in aliquots at -20°C.
To assess serum inhibition of monocyte chemotaxis, undiluted patient's serum was incubated with equal portions of a MN cell suspension from a standard normal adult donor for 30 min, washed twice with Hanks' balanced salt solution, and resuspended in RPMI for the chemotaxis determination.
To assess possible cytotoxicity of drugs added to mononuclear preparations, Ficoll-Hypaque separated cells from four normal adults were washed twice with Hanks' balanced salt solution and 
RESULTS

PATIENTS WITH INCREASED SUSCEPTIBILITY TO INFECTION
Of the 33 patients tested, one child had a persistent decrease from normal age-matched controls on nine separate occasions when he was not receiving parenteral antifungal medications (Table I ). This 9-year-old bov has severe chronic mucocutaneous candidiaiis, bronihiectasis, f&lure to thrive, hypothyroidism, and recurrent otitis media and sinusitis. He has not responded to transfer factor, levamisole, or lymphocyte transfusions and requires repeated courses of IV amphotericin B or miconazole. . In virro, he has decreased lymphocyte blastogenic response to C. albicans antigen and decreased macrophage inhibition factor production. Quantitative immunoglobulins, B-and T-cell enumeration, neutrophil chemotaxis, mixed lymphocyte culture reactivity. and in virro phytohemagglutinin reactivity were normal. In addition to the chemotactic defect, in vitro monocyte killing of C. albicans was decreased on three separate occasions. Staphylococcal killing was normal.
PATIENTS WITH ATOPIC DERMATITIS
Mean monocyte chemotaxis values ( f S.E.) of the atopic patient groups were compared with values from age-matched normal control groups (based on 86 normal individuals previously reported from our laboratory) (Ref. 15 ; Fig. 2) . Mean values (* S.E.) for patient groups 1 month to 2 years (36 f 27) and 3 to 5 years (68 * 50) were not significantly different from controls (3 1 k 6 and 71 f 15, respectively). Although mean monocyte chemotaxis in the 6-to 10-year (125 f 33) group was lower than that in controls, this decrease was not statistically significant. However, atopic patients I I years and older as a group (123 f 24) had significantly reduced mean values from controls (215 f 12). No significant correlation was found between monocyte chemotaxis and serum IgE levels, blood eosinophil counts, or symptoms.
When individual patients were compared, 3 patients ( 
DRUG EFFECTS
Results of in vitro drug effects on monocyte chemotaxis are presented in Table 3 . Concentrations of aminophylline (8) therapeutic range resulted in greater than 35% decrease from control levels (cells without added drug). Increasing concentrations of hydrocortisone, ephedrine, and diphenhydramine resulted in depression of chemotaxis. However, the inhibiting levels of hydrocortisone were generally in excess of plasma cortisol levels following IV administration in status asthmaticus (100 &I00 ml) (5) . The inhibiting concentrations of ephedrine and diphenhydramine also exceeded observed plasma concentrations following PO administration (2, 18) . Aspirin levels of 20 and 50 ml/dl produced significant inhibition of chemotaxis; however, these same levels caused significant loss of cell viability at 18 hr as measured by trypan blue exclusion (73 and 53% viability, respectively.) For the other tested drugs, the percentage of mononuclear cell viability exceeded 90% for all drug centrations except diphenhydramine (250 pg/ml, 84% at 3 hr, 88% at 18 hr; 1000 pg/ml, 59% at 18 hr, 250 pg/ml, 45% at 18 hr), and hydrocortisone (100 pg/ml, 86% and 250 pg/ml, 83%).
In vivo aspirin studies are shown in Figure 3 . Aspirin levels ranged between 18 and 29 mg/dl with a mean of 22.4 mg/dl. A predose mean neutrophil chemotaxis value of 232 migrated cells was not significantly different from a postmean value of 249. When monocyte chernotaxis was measured concurrently, a uniform decrease in 7 of 8 subjects was observed. A preaspirin mean value of 137 cells significantly differed from a postaspirin value of 100 cells.
DISCUSSION
Increased interest has developed concerning the role of monocyte chemotaxis in normal host defense and possible aberrations of this function in disease states or secondary to pharmacologic agents. The agarose technique provides a simple and reproducible method to study chemotaxis and allows confirmation and extension of data previously obtained by the Boyden method (6, 15, 2 1 ).
Defective monocyte chemotaxis has previously been described in severe chronic mucocutaneous candidiasis (I 1. 27). Our patient resembles Gallin's patient who, in addition to mucocutaneous candidiasis, has recurrent pyogenic infections, defective delayed hypersensitivity, and lack of response to transfer factor. In addition, in vitro monocyte killing of C. albicans has been consistently impaired in our patient and may contribute to his increased clinical severity. Combination defects of monocytes involving two separate functions, namely directed movement and killing, have a parallel in combined polymorphonuclear defects (20).
Investigations of monocyte function in patients with atopic dermatitis are a logical extension of previous studies noting abnormalities of cell-mediated immunity in this disease (13, 19. 23) . Immunodeficient states associated with eczema, i.e., Wiskott-Aldrich syndrome, also have defects in monocyte chemotaxis, apparently due to increased levels of circulating lymphocyte-derived chemotactic factor (1).
Rogge and Hanifm (25) , using a Boyden chamber method, found decreased polymorphonuclear chemotaxis in seven of I I adult atopic patients and defective monocyte chemotaxis in four of four patients. Impairment of cell movement correlated with clinical severity but not with total serum IgE. Subsequent studies (14) showed inhibition of PMN chemotaxis with sera from three patients. During clinical remissions, these sera did not cause inhibition. In another study, Furakawa and Altman (lo), using Boyden chambers, noted depressed monocyte chemotaxis in 8 of 17 atopic children with hyper-IgE (>I000 IU/ml) and two of nine nonhyper-IgE atopic children. No cell-directed chemotactic inhibition was found in the plasma of these patients. Snyderman el al. (29) found inhibition of monocyte chemotaxis in 8 of 14 atopic dermatitis patients. Of these 8 patients, sera from 5 of 6 tested demonstrated inhibition of chemotaxis. Depressed monocyte chemotaxis did not correlate with serum IgE concentrations, severity of eczema, or the presence of infection. Furthermore, in vitro incubation of normal monocytes with histamine or IgE myeloma did not cause inhibition.
Our study using an agarose method showed a lower percentage of patients (3 of 22) Multiple reasons may account for the differences among studies in the percentage of monocyte chemotaxis defects observed. First, chemotaxis methodologies may selectively enhance or suppress cell movement. Gallin el al. (12) . for exam~le, noted abnormal random monocyte chemotaxis patients with Chediak-Higashi syndrome when a Boyden chamber was used. However, with a capillary tube system (which, like the agarose system, does not use a filter), normal chemotaxis was observed. Other major differences in chemotaxis methodologies include choice of chemoattractants (lymphocyte-derived chekotactic factor in Snyderman's study; zymosam-activated serum and bacterial chemotactic factor bv Furakawa et al.; zymosan-activated serum in our study) and methods to study serum inhibitors (preincubation and wash in our studies and the studies of Furakawa et al., direct addition of 1Wo serum to cell preparations by Snyderman et 01.).
A second major area causing differences among these three studies is patient and control selection. As shown by our previous study (IS), monocyte chemotaxis is age-dependent with values increasing with age. In the study of Snyderman el al., 5 of 8 patients with "depressed" monocyte chemotaxis are under 5 years of age but are compared to 98 normal adult subjects and 5 diseasecontrol children with recurrent infections. If only adult values were used in our study, an additional 6 patients would have "depressed monocyte chemotaxis.
Patient selection is also hampered in all studies by the inability to clinically define with accuracy the presence of infections and the extent and severity of skin involvement. As shown by Leyden et al. (17) atopic patients apparently "free" of skin infection have increased numbers of Staphylococcus aureus in clinically normal skin. Staphylococcal products also demonstrate a complex pattern in vitro of either stimulation or inhibition of monocyte and neutrophil chemotaxis (26) .
Finally, drug administration to atopic patients may influence chemotactic results. Our in vitro data showed suppression of monocyte chemotaxis by theophylline in the therapeutic range. These in vilro studies do not take into account the effect of chronic administration or the action of drug metabolites, protein binding, and other factors operative in vivo. However, they confirm previous studies of cell movement which showed a decreased chemotactic response to agents which increase cyclic AMP (4, 9, 24, 30) .
Our observation of greater suppression of monocyte than of neutrophil chemotaxis with PO administered aspirin parallels data from animal studies and suggests selective inhibition of chemotaxis depending on cell type. In rabbits, Bore1 and Feurer (3) noted a marked in vitro inhibition of macrophage chemotaxis with phenylbutazone and sodium salicylate but little effect on PMN chem-otaxis. DiRosa et a/. ( 
